Such molecules might also provide the advantage of not activating downstream immune effector functions against endothelia, including the classical complement pathway and/or antibody-dependent cytotoxicity via FcγR-bearing immune cells, as this might have undesirable consequences in diseases like hereditary angioedema. Here, FCGR2A is linked to hereditary angioedema.